Agios Pharmaceuticals, Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS12
PHASE 3 / 2-39
RECRUITING3
READOUTS ≤12 MONTHS0
READOUT SLIPPED >6 MO0%
Delay Index: of 8 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +2.4 months). See all sponsors →
Open Agios Pharmaceuticals, Inc. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| AG-348 NCT03692052 |
P2 | Active, not recruiting | Thalassemia | 20 | 2020-08-20 (-15 mo) |
| Mitapivat NCT04770753 |
P3 | Active, not recruiting | Non-Transfusion-dependent Alpha-Thalassemia; Non-Transfusion-dependent Beta-Thalassemia | 194 | 2023-11-13 (+3 mo) |
| ENERGIZE-T NCT04770779 |
P3 | Active, not recruiting | Transfusion-dependent Alpha-Thalassemia; Transfusion-dependent Beta-Thalassemia | 258 | 2024-04-11 (+3 mo) |
| ACTIVATE-KidsT NCT05144256 |
P3 | Active, not recruiting | Pediatric Pyruvate Kinase Deficiency; Pediatric Hemolytic Anemia | 49 | 2024-05-03 (-6 mo) |
| ACTIVATE-Kids NCT05175105 |
P3 | Active, not recruiting | Pediatric Pyruvate Kinase Deficiency; Pediatric Hemolytic Anemia | 30 | 2024-12-13 (+2 mo) |
| Mitapivat NCT05031780 |
P2/3 | Active, not recruiting | Sickle Cell Disease | 286 | 2025-10-30 (+2 mo) |
| Tebapivat NCT05490446 |
P2 | Active, not recruiting | Myelodysplastic Syndromes | 87 | 2026-03-17 (+4 mo) |
| Tebapivat NCT06924970 |
P2 | Active, not recruiting | Sickle Cell Disease | 59 | 2026-05-12 |
| ENERGIZEKids NCT07517133 |
P3 | Recruiting | Non-Transfusion-dependent Alpha-Thalassemia; Non-Transfusion-dependent Beta-Thalassemia | 45 | 2029-03 |
| ENERGIZEKids-T NCT07506863 |
P3 | Recruiting | Transfusion-dependent Alpha-Thalassemia; Transfusion-dependent Beta-Thalassemia | 54 | 2029-06 |
| Mitapivat NCT07656415 |
P3 | Recruiting | Sickle Cell Disease | 159 | 2029-08 |
| PreVail NCT07859423 |
P2/3 | Not yet recruiting | Polycythemia Vera | 245 | 2030-08 |